Objective: To compare outcomes for patients with hepatocellular carcinoma (HCC) treated with either liver resection or transplantation. Methods: A retrospective, single-institution analysis of 413 HCC patients from 1999 to 2009. Results: A total of 413 patients with HCC underwent surgical resection (n = 106) and transplantation (n = 270) or were listed without receiving transplantation (n = 37). Excluding transplanted patients with incidental tumors (n = 50), 257 patients with suspected HCC were listed with the intent to transplant (ITT). The median diameter of the largest tumor by radiography was 6.0 cm in resected, 3.0 cm in transplanted, and 3.4 cm in the listed-butnot-transplanted patients. Median time to transplant was 48 days. Recurrence rates were 19.8% for resection and 12.1% for all ITT patients. Overall, patient survival for resection versus ITT patients was similar (5-year survival of 53.0% vs 52.0%, not significant). However, for HCC patients with model end-stage liver disease (MELD) scores less than 10 and who radiologically met Milan or UCSF (University of California, San Francisco) criteria, 1-year and 5-year survival rates were significantly improved in resected patients. For patients with MELD score less than 10 and who met Milan criteria, 1-year and 5-year survival were 92.0% and 63.0% for resection (n = 26) versus 83.0% and 41.0% for ITT (n = 73, P = 0.036). For those with MELD score less than 10 and met UCSF criteria, 1-year and 5-year survival was 94.0% and 62.0% for resection (n = 33) versus 81.0% and 40.0% for ITT (n = 78, P = 0.027). Conclusions: Among known HCC patients with preserved liver function, resection was associated with superior patient survival versus transplantation. These results suggest that surgical resection should remain the first line therapy for patients with HCC and compensated liver function who are candidates for resection. (Ann Surg 2011;254:527-538) W orldwide, hepatocellular carcinoma (HCC) has been estimated to be the third most common cause of cancer-related death. [1] [2] [3] In vast regions of the world including sub-Saharan Africa and East-Asia, HCC is the most common cause of cancer-associated mortality surpassing gastric and lung cancers in incidence and mortality. The incidence of HCC remains far lower in the United States and Europe but has dramatically increased in the past several decades. 4
The increase in HCC prevalence is anticipated to continue in both the United States and Europe over the next several decades, primarily because of the hepatitis C virus and to a lesser extent because of emigration from endemic regions, nonalcoholic steatohepatitis, and the spread of the hepatitis B virus. 2, [4] [5] [6] The best potential curative therapies available to treat patients who develop HCC are liver resection or transplantation. [7] [8] [9] Unfortunately, because of intrinsic liver dysfunction (limiting resection), lack of liver donor availability (limiting transplant), and late detection (limiting both), only a small subset of patients are candidates for curative therapies. 10, 11 Increasingly, a role for hepatic ablative therapies has been recognized, but such therapies in Western series have not been universally associated with equivalent patient outcomes. [12] [13] [14] Nonetheless, determination of which curative intent therapies to provide patients remain poorly defined. 15 Although outstanding outcomes have been observed with the use of ablative techniques at select centers, particularly for tumors smaller than 3 cm, most studies report resection or transplantation as superior therapies in the management of HCC. Thus, ablative therapies have generally been restricted as a bridge therapy before transplantation, or as palliative therapy for patients who are not candidates for either resection or transplantation. [12] [13] [14] Similarly, because of restrictions of size on candidacy for transplantation (those who satisfy the Milan or UCSF [University of California, San Francisco] criteria) and intrinsic regenerative abnormalities from sequelae of cirrhosis (limiting the ability to provide resective therapies), many patients are potential candidates for only resection or transplantation, respectively. 16 Several studies have compared outcomes for patients with HCC treated with various curative-intent therapies. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The majority of studies have mainly limited their analysis to patients satisfying current transplantation guidelines by size parameters. Those data have generally observed equivalent overall outcomes for patients who have been treated with either resection or transplantation. To better define the relative outcomes for patients who theoretically might be candidates for either resection or transplantation, we compared outcomes from a single institution that actively practices both resective and transplantation approaches in the management of HCC.
Memorial Hospital system has also prospectively collected an HCC registry for patients who were considered for transplantation beginning in 2001. This data set was queried to identify patients with HCC who were listed and/or underwent liver transplantation for HCC. Merging of these data sets identified the patient pool for evaluation in this study. Among all HCC patients identified, this study examined outcomes for patients who were provided curative-intent treatment for HCC.
Patients who underwent hepatic resection from 1999 to 2009 or underwent liver transplantation from 2001 to 2009 were examined. Overall, 413 patients with HCC treated with either resection or liver transplantation were identified. All patients were stratified by treatment strategies that included resection, incidental transplant (HCC noted on final pathology report), nonincidental transplant (known HCC before transplantation), and listed but not transplanted (known HCC, but donor organ not available). Those patients with nonincidental transplants and those who were listed with known HCC but not transplanted were defined as the intent-to-transplant (ITT) group.
Model end-stage liver disease (MELD) scores were prospectively collected in the transplantation cohort and were determined retrospectively in most resected candidates. Tumor sizes were determined by radiographic imaging, including computerized tomography, magnetic resonance imaging, or ultrasonography. Patients with missing data were excluded from each respective analysis. Survival was determined by the tumor registries and independently verified during data collection with the examination of the National Social Security Death Index. Patients lost to follow-up were censored at the time of last contact or confirmed date of death. Survival was calculated from the time of initial diagnosis to the date of last contact or death. Recurrence-free survival (RFS) analysis was calculated from the date of initial resection or transplantation to the date of documented recurrence of disease or death.
All patients were also stratified by MELD scores and radiographic size: Milan (1 lesion < 5 cm, or up to 3 lesions < 3 cm), or UCSF (single lesion ≤ 6.5 cm, multiple lesions ≤ 3 cm, largest tumor diameter if multiple ≤ 4.5 cm, and total tumor diameter if multiple ≤ 8 cm). [27] [28] [29] To evaluate the effects of intrinsic liver function and tumor size, subgroup analysis was performed with patient subcategorization as either meeting Milan and MELD less than 10 or UCSF and MELD less than 10. Rates of recurrences were analyzed for the various resective procedures (wedge/partial, formal right, extended right, formal left, and extended left) and their margin status (positive or negative). The subgroup of resected patients requiring secondary procedures was also examined.
Statistical analysis was performed with SPSS version 18.0 (PASW), released July 30, 2009 (IBM Corporation, Somers, NY). Chi-square test was used for categorical variables and one-way analysis of variance for age, MELD score, and radiological size. Survivals were analyzed for the entire cohort of patients and for each subgroup that met size or MELD criteria. Survival curves were performed by Kaplan-Meier method and the Log-Rank (Mantel Cox) test was used for survival comparisons. Survivals were expressed as median, 1-year, 5-year, and 7-year percentages. Statistical significance was defined as P < 0.05.
RESULTS

Patient and Tumor Demographics for the Cohort
Overall, we identified more than 1400 patients who were evaluated for the treatment of HCC at the University of Miami/Jackson Memorial Hospital. Of these, 413 patients with HCC underwent surgical resection (n = 106), underwent transplantation (n = 270), or were listed without receiving transplantation (n = 37) (Table 1, Fig. 1 ).
Median age of the cohort of 413 patients was 58 years with a 3:1 male predominance (Table 1 ). There were no significant differences in age or sex ratios between resection and ITT patient groups. A significantly higher fraction of ITT patients than those who underwent resection had viral hepatitis, particularly hepatitis C (74.3% and 28.3%, respectively, P = 0.0001) and overall a significantly increased median MELD score (11 vs 6, respectively, P = 0.0001). Mean radiographic tumor size or the largest tumor in cases of multifocal disease was considerably larger in the resection group (6 cm and 3.0 cm respectively, P = 0.0001).
Tumor characteristics for the cohort were analyzed in Table 2 . Overall, the ITT group as compared to the resection group had considerably more right hepatic lesions (77.8% and 59.4%, respectively), bilateral lesions (10.4% and 5.4%, respectively), and multifocal disease (48.2% and 15.1%, respectively). Median pathological sizes were significantly greater in the resection group than the ITT group (6.0 cm vs 3.0 cm, respectively, P < 0.0001). Similar differences were noted on final pathological measurements; although, pathological sizes were slightly greater than radiographic sizes particularly in the transplantation group, likely because of the delay between imaging and definitive therapy. Tumor morphology was similar between the resection and ITT groups with the majority being low grade (73.6%), representing well or moderately differentiated tumors. Most tumors in the resection and ITT groups did not demonstrate lymphatic (92.5% and 59.9%, respectively) or vascular invasion (70.8% and 59.9%, respectively). Overall, recurrences were noted in 13.3% of the entire cohort, with the majority of these occurring within the liver or lung. Overall, recurrences were documented in 19.8% of the resection group and 12.1% of the ITT group with no significant difference between the 2 groups (P = 0.335). Of note, 4 patients had fibrolamellar HCC. Also, no evidence for fibrosis or cirrhosis was noted in 35 of 106 (33%) patients who underwent resection. All patients who underwent transplantation had fibrosis or cirrhosis.
Treatment by Size and Liver Function
Radiographic tumor size and MELD scores were used to compare which patients underwent resection or transplantation ( Fig. 2 ). As noted in Figure 2 , few resections were performed for patients with MELD scores more than 12 to 13 and few liver transplants were performed in patients with tumors larger than 6.5 cm. Thus, overlap of patients receiving liver resection or transplantation was observed primarily for tumors smaller than 6.5 cm and MELD scores less than 13. Table 3 displays the number of patients in each subgroup satisfying Milan (<5 cm), or UCSF criteria (<6.5 cm), and having MELD scores < or ≥ 10. The majority of patients in the resection groups had biological MELD scores less than 10 (84.9%) and in the ITT group the majority of patients (67.3%) had a MELD score 10 or more. Resection and ITT patients who met Milan criteria and had MELD scores less than 10 were 31.1% and 30.4% of their respective groups. Resection and ITT patients who satisfied UCSF criteria and had MELD scores less than 10 were 24.5% and 28.4% of their respective groups. Table 4 summarizes the treatment strategies used in the 106 patients who underwent hepatic resection. Techniques of liver resection and parenchymal transection varied widely depending upon the operative surgeon. Overall, the majority of resections were partial hepatic lobectomies (55.7%). Right hepatic lobectomies were performed in 31.1% and left lobectomies in 10.4% of patients. Resection margins on final pathology were reported as positive in 17.9% 
Degree of Resection and Incidence of Recurrence by Margin Status
TABLE 1. Patient Demographics
Resection Versus Hepatic Transplantation
On the basis of the distribution of therapies as a function of MELD score and radiographic tumor size, few patients were potential candidates for either hepatic resection or transplantation. Specifically, patients with HCC were generally not considered candidates for liver transplantation if the tumor exceeded Milan criteria or UCSF criteria (single lesion ≤ 6.5 cm, multiple lesions ≤ 3 cm, largest tumor diameter if multiple ≤ 4.5 cm, total tumor diameter if multiple ≤ 8 cm, and no extrahepatic or vascular invasion). 6 Use of hepatic resection was generally limited to patients with relatively preserved liver synthetic function, without ascites and a sufficiently large hepatic remnant after resection to prevent death from liver failure. 30, 31 Upon initial analysis, when comparing resection versus transplantation, we found no significant difference between the 2 groups. However, all patients who were listed but not transplanted were dead at less than 6 years from listing ( Table 5 , Fig. 3 ).
Given our objective was to understand the relative benefit of resection versus transplantation, we first focused on patients whose tumor size met Milan or UCSF criteria (270 and 288 patients, respectively, Table 5 ). First, univariate analysis demonstrated no significant difference in survival for patients who met Milan criteria between the resection and ITT groups. Similarly, univariate analysis demon-strated there was no significant difference in survival for tumors that met either Milan or UCSF criteria between the resection and ITT groups ( Table 5 , Figs. 4A, C). Of note, however, a trend for increased survival for patients in the first 2 years was observed in the resection group although not statistically significant (resection vs ITT: met Milan, P = 0.146, met UCSF, P = 0.089). This decreased short-term survival with transplantation was largely attributable to patients who were listed but not transplanted, as they demonstrated poor long-term survival.
We therefore next evaluated whether there was a survival difference between the resection and ITT groups for those patients who met Milan or UCSF criteria and demonstrated lesser degrees of liver dysfunction. 32 Specifically, a MELD score of less than 10 is associated with a 1-year survival rate of 95%, when excluding the presence of a HCC. 32 Hepatic transplantation is known to have a 1-year survival rate in the range of 85% to 90%, with mortality related to both technical challenges of transplantation and problems related to immunosuppression. 33 We posited therefore that for HCC patients with a MELD score less than 10 improved survival rates might be observed with hepatic resection.
Median, overall 1-, 5-, and 7-year survivals were calculated for all patients with their respective treatment strategies and for those resection and ITT patients subcategorized for met MILAN or UCSF criteria and specified MELD scores (<10, ≥10) ( Table 5 ). There was a statistically improved survival in the resection group compared with the ITT group for those patients who met MILAN or UCSF criteria and had a MELD score less than 10 ( Table 5 , Fig. 4B, 4D ). However, no statistically significant difference in survival was observed when those who were listed but not transplanted were excluded from the analysis ( Table 5 ). Table 5 also reports additional survivals by various categorization and treatment strategies. analysis. Upon our initial analysis of all patients, without stratification for size and MELD less than 10, we noted a trend for an increased 5-year RFS in those patients who underwent transplantation compared with resection (60% and 45% respectively, P = 0.063) ( Table 6 , Fig. 5 ). When evaluating patients who met Milan or UCSF criteria, transplanted patients compared with resected patients had a decreased 1-year but increased 5-year RFS ( Table 6 , Fig. 6 ). However, when evaluating patients who met Milan or UCSF criteria, with a MELD less than 10, RFS appeared to be equivalent between the transplanted and resected groups ( Table 6 , Fig. 5 ). These data suggest that more advanced MELD scores were associated with increased tumor recurrence risk in the resection group.
TABLE 2. Tumor Characteristics
DISCUSSION
Liver resection, radiofrequency ablation, and transplantation are recognized as effective palliative and potentially curative therapies for patients who develop HCC. However, the optimal therapeutic approach for HCC remains undefined. Recent work from Nathan et al has demonstrated that choice of HCC treatment is somewhat more strongly related to surgeon specialty than to certain clinical factors. 34 The University of Miami/Jackson Memorial Medical Center treats a large number of patients with HCC using both hepatic resection and transplantation approaches. We sought to evaluate patient outcomes for HCC retrospectively with the goal of comparing outcomes of resection versus transplantation in patients who were initially candidates for either approach. We also specifically sought to evaluate the impact of size and MELD score on overall survival and RFS between the 2 treatment strategies.
We compared outcomes utilizing a retrospective, ITT analysis. We excluded patients with HCC discovered incidentally at pathological examination of the excised liver, because such transplantation was not intentionally performed for HCC and is thus not applicable to defining treatment for known HCC.
In the first analysis, we included all patients who were listed for transplantation, irrespective of whether the patient ultimately received liver transplantation. This analysis is the most inclusive and reflects the risks and mortalities associated with listing patients for transplantation in a setting where donor livers are limiting. Within that cohort, we observed a trend for increased overall 1-and 2-year survival rates in the resection group. We also observed equivalent overall 5-year survival rates for patients treated with either resection or attempt at transplantation for HCC ( Table 5 , Fig. 4 ). In the focused analysis of the subset of patients with relatively preserved liver function (MELD < 10) who were potential candidates for either therapy (ie, they met Milan or UCSF criteria), improved overall survival was observed for surgical resection versus transplantation ( Table 5 , Fig.  4B, 4C) .
To focus on clinical outcomes relating to surgery rather than to graft availability, we then eliminated from our analysis patients who were listed but not transplanted. Among patients who met Milan or UCSF criteria, we observed diminished 1-year overall survival and RFS for liver transplantation versus resection ( Table 6 , Fig. 6A, 6B) . This was because of decreased overall survival in the acute period after transplantation. Such acute deaths are typically from technical challenges associated with transplantation and/or immunosuppression rather than recurrence of disease. Nevertheless, at 5 years, there was increased RFS in patients who underwent liver transplantation rather than resection. Limiting the analysis to patients who had preserved liver function (ie, MELD < 10) and met Milan or UCSF criteria for transplantation, we observed no difference in 5year RFS for resection versus liver transplantation. One interpretation of these data is that for patients who are candidates for either therapy, liver resection can result in equivalent long-term survival without the risks of organ nonavailability or the acute postoperative complications associated with transplantation and immunosuppression. Among patients who survive the transplantation procedure beyond the first perioperative year, however, liver transplantation resulted in greater RFS, potentially because of the replacement of the cancer-prone organ.
To date, a number of series have attempted to compare outcomes for HCC patients who were potentially candidates for either resection or transplantation. A recent review by Rahbari et al 6 from Heidelberg reviewed 9 such studies. [17] [18] [19] [20] [21] [22] [23] [24] [25] Among those studies, most identified no significant difference in patient survival rates. Only in 4 studies were patients who failed to obtain new liver organs considered in the comparisons. Thus, the results of the other studies might exclude the mortalities resulting from organ nonavailability. Such an analysis would fail to reflect the realities facing the surgeon and patient choosing transplantation over resection. Furthermore, only the study by Facciuto et al 23 (n = 161 patients) specifically excluded patients found to have HCC incidental to liver transplantation performed for other indications. Such patients would not accurately reflect the true patient pool under consideration here because inclusion of such patients would artificially increase outcomes related to transplantation for HCC.
For these reasons, the series reported here with its 413 patients is among the largest to examine the benefits of resection versus transplantation in patients who may be candidates for both treatment strategies. This study is also the first study to evaluate survival outcomes for such patients with relatively preserved liver function (MELD < 10). Model end-stage liver disease scores less than 10 are generally associated with normal or well-compensated liver function and this cohort in general carries a 98% to 99% 3-month survival rate and 95% 1-year survival rate in the absence of HCC. 32 Some patients with MELD scores less than 10 may have ascites, however, rendering them poor candidates for hepatic resection. Our finding of improved survival with resection for HCC among the patient cohort with tumors that met Milan or UCSF criteria and MELD less than 10 is of particular interest, but certainly needs confirmation in nonoverlapping data sets. 28 Nonetheless, on the basis of this retrospective series, if a patient with preserved liver function has a HCC and is a candidate for hepatic resection, this series supports superiority of resection. Moreover, the number of patients requiring reresections or transplantation after a recurrence were limited (10 and 4, respectively); however, this series indicates that both strategies can provide favorable survival outcomes and that repeat therapies can be associated with long-term survival.
There are certainly limitations of this data set and our analysis. The analysis is retrospective and thus limited by the data collected and by the lack of patient randomization. One consequence of this is that recurrence in patients treated with resection might be underreported because those patients did not undergo the very close postoperative follow-up screening that transplantation patients are given. As well, our analysis assumes that patients with small liver tumors in the MELD less than 10 group were candidates for either therapy; however, almost certainly some were actually not candidates for resection, for example, because of the presence of ascites or tumor multifocality such that a margin-negative resection with a sufficient hepatic remnant would be impossible. Similarly, 100% of the transplanted patients had hepatic fibrosis or cirrhosis, whereas 28% of the resection group had minimal or no evidence for hepatic fibrosis or cirrhosis. Such patients likely have better prognosis cancers and may have contributed to the relatively low recurrence rate observed in the resection group. [17] [18] [19] [20] [21] [22] [23] [24] [25] Furthermore, although we identified all patients with ITT, we do not know how many patients were treated with intentto-resect. All patients who underwent resection were included, but we do not know how many patients who were believed to be candidates for resection preoperatively were later found to be poor candidates at the time of exploration and treated with ablative therapies or even later transplanted. Multifocal tumors were more frequently encountered in the transplantation group; this may have biased outcomes in favor of hepatic resection. Finally, a much larger fraction of patients with HCC and cirrhosis from hepatitis C underwent transplantation. Outcomes for HCC patients with hepatitis C have been noted to be worse than HCC arising from hepatitis B, [17] [18] [19] [20] [21] [22] [23] [24] [25] potentially disproportionately decreasing survival within the transplantation group. Such limitations might bias the analysis in favor of resection. Conversely, the considerably larger tumor size noted in the resection group might bias the results in favor of transplantation.
This study does not address how to integrate ablative therapies such as radiofrequency ablation into the treatment algorithm for patients with HCC. Certainly, many centers have developed excellent local tumor control with such therapies, particularly for tumors smaller than 2 or 3 cm. Identifying patients who might have been treated equally effectively with radiofrequency ablation is of critical interest. If equivalent local tumor control rates for HCC could be obtained, ablation might become first line therapy because of its reduced invasiveness and increased preservation of liver mass. In this series, radiofrequency ablation and other ablative therapies were reserved for patients deemed not candidates for resection or used in lieu of transplantation with transplantation reserved for a later date. Also, although it is now used extensively as a bridge to transplantation in the current practice at University of Miami/Jackson Medical Center, during the period analyzed radiofrequency ablation was not universally applied to all listed patients with known HCC tumors. Also, although molecular insights are being made in the pathogenesis of HCC, no clearly effective adjuvant therapies currently exist. [35] [36] [37] [38] [39] [40] Of course, determining the optimal therapy for HCC will require prospective, randomized clinical trials across multiple institutions. Acknowledging the limitations of this study, however, several hypotheses and a potential framework for clinical treatment guidelines can be drawn from our analysis. Currently, most transplantation guidelines suggest that resection should be performed in patients who are candidates for either approach. 6 Consistent with those guidelines, our data support the use of liver resection as primary therapy for patients who develop HCC, if the patients are candidates for either hepatic resection or transplantation. In patients with preserved liver function who also meet current transplantation guidelines, the use of resection is superior for patient survival because of limited organ availability and transplantation-associated morbidity and mortality; although the cancer cure rate for the subset of patients who do receive a liver might be equivalent or better. In our cohort, the average waiting time to transplantation was 48 days. In other settings, reduced organ availability and longer wait times would necessarily be associated with increased mortality and disease progression. Our data balanced against the current, chronic shortage of available livers for transplantation supports the use of resection as primary therapy for HCC patients who are candidates for resection, particularly in those with preserved liver function. As such, transplantation could be reserved for the resection candidate group as salvage therapy after recurrence. This treatment strategy will not only preserve quality of life but may improve survival, while at the same time reducing demand for available donor livers.
FIGURE 6.
Recurrence-free survival for hepatic resection and transplant patients excluding incidentally identified hepatocellular carcinomas by tumor size for all MELD or MELD score less than 10. A, Milan criteria; B, UCSF criteria; C, Milan criteria with MELD score less than 10; and D, UCSF criteria with MELD score less than 10.
DISCUSSANTS
D. Geller (Pittsburgh, PA):
The authors conclude that for known HCC patients with preserved low-MELD-score liver function, surgical resection should be the first line of therapy. This is an important contribution, given the global organ donor shortage. And these recommendations are consistent with several other recent studies supporting first-line resection and then salvage liver transplant for HCC recurrence. I have several questions.
First, given the commendable short median wait time of only 48 days to transplant seen in Miami, what was the reason for dropout or failure to achieve transplant in 37 patients? Was it due to tumor progression? Second, approximately 30% of the resection patients were noncirrhotic, which arguably is a different group of patients, and most surgeons and societies uniformly advocate resection. Was a separate survival analysis done for the low-MELD-score patients undergoing resection who were actually cirrhotic? Third, the ITT group had a much greater percentage of hepatitis C viral patients, 74% versus 28%, and a greater number of multifocal tumors, 48% versus 15%, compared with resection. Do you think that these 2 factors, high HCV and high multifocality, had an impact on the overall survival analysis?
Finally, in the resection group, the 20% recurrence rate for HCC is somewhat lower than that reported for other groups. Do you think this is in part due to the inclusion of the noncirrhotic patients?
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